Update on the current status of cytomegalovirus vaccines

References

• Demmler GJ. Congenital cytomegalovirus infection and disease. Semin. Pediatr. Infect. Dis.10(3), 195–200 (1999).
   Google Scholar
• Stagno S, Pass RF, Cloud G et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA256(14), 1904–1908 (1986).
   PubMed Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev. Med. Virol.17(5), 355–363 (2007).
   PubMed Web of Science ®Google Scholar
• Cheeran MC, Lokensgard JR, Schleiss MR. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev.22(1), 99–126 (2009).
   PubMed Web of Science ®Google Scholar
• Bale JF, Miner L, Petheram SJ. Congenital cytomegalovirus infection. Curr. Treat. Options Neurol.4(3), 225–230 (2002).
   PubMedGoogle Scholar
• Cannon MJ, Davis KF. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health5, 70 (2005).
   PubMed Web of Science ®Google Scholar
• Ahlfors K, Ivarsson SA, Harris S. Report on a long-term study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand. J. Infect. Dis.31(5), 443–457 (1999).
   PubMedGoogle Scholar
• Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med.344(18), 1366–1371 (2001).
   PubMed Web of Science ®Google Scholar
• Novak Z, Ross SA, Patro RK et al. Cytomegalovirus strain diversity in seropositive women. J. Clin. Microbiol.46(3), 882–886 (2008).
   PubMed Web of Science ®Google Scholar
• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol.17(4), 253–276 (2007).
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med.326(10), 663–667 (1992).
   PubMed Web of Science ®Google Scholar
• Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol.325, 417–470 (2008).
   PubMed Web of Science ®Google Scholar
• Stagno S, Pass RF, Dworsky ME et al. Congenital cytomegalovirus infection: the relative importance of primary and recurrent maternal infection. N. Engl. J. Med.306(16), 945–949 (1982).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Ross SA, Novak Z et al. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA303(14), 1375–1382 (2010).
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA289(8), 1008–1011 (2003).
   PubMed Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia11(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: a Tool for Decisionmaking. Committee to Study Priorities for Vaccine Development Division of Health Promotion and Disease Prevention, Institute of Medicine, Washington, DC, USA (1999).
   Google Scholar
• Arvin AM, Fast P, Myers M, Plotkin S, Rabinovich R. Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin. Infect. Dis.39(2), 233–239 (2004).
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Heineman TC. Progress toward an elusive goal: current status of cytomegalovirus vaccines. Expert Rev. Vaccines4(3), 381–406 (2005).
   PubMed Web of Science ®Google Scholar
• Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med.360(12), 1191–1199 (2009).
   PubMed Web of Science ®Google Scholar
• Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology197(1), 143–158 (1993).
   PubMedGoogle Scholar
• Tugizov S, Navarro D, Paz P, Wang Y, Qadri I, Pereira L. Function of human cytomegalovirus glycoprotein B: syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies. Virology201(2), 263–276 (1994).
   PubMedGoogle Scholar
• Marshall GS, Rabalais GP, Stout GG, Waldeyer SL. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J. Infect. Dis.165(2), 381–384 (1992).
   PubMed Web of Science ®Google Scholar
• Marshall GS, Stout GG, Knights ME et al. Ontogeny of glycoprotein gB-specific antibody and neutralizing activity during natural cytomegalovirus infection. J. Med. Virol.43(1), 77–83 (1994).
   PubMed Web of Science ®Google Scholar
• Navarro D, Lennette E, Tugizov S, Pereira L. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J. Med. Virol.52(4), 451–459 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang C, Buchanan H, Andrews W, Evans A, Pass RF. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding. J. Clin. Virol.35(3), 338–342 (2006).
   PubMedGoogle Scholar
• Zhang C, Pass RF. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine. Vaccine23(4), 507–510 (2004).
   PubMed Web of Science ®Google Scholar
• Colugnati FA, Staras SA, Dollard SC, Cannon MJ. Incidence of cytomegalovirus infection among the general population and pregnant women in the United States. BMC Infect. Dis.7, 71 (2007).
   PubMed Web of Science ®Google Scholar
• Griffiths PD, McLean A, Emery VC. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine19(11–12), 1356–1362 (2001).
   PubMed Web of Science ®Google Scholar
• Griffiths P. The beginning of the end of a long wait for a vaccine against cytomegalovirus. Rev. Med. Virol.19(3), 117–119 (2009).
   PubMedGoogle Scholar
• Griffiths PD. CMV vaccine trial endpoints. J. Clin. Virol.46(Suppl. 4), S64–S67 (2009).
   Google Scholar
• Pass RF. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J. Clin. Virol.46(Suppl. 4), S73–S76 (2009).
   PubMedGoogle Scholar
• Dekker CL, Arvin AM. One step closer to a CMV vaccine. N. Engl. J. Med.360(12), 1250–1252 (2009).
   PubMed Web of Science ®Google Scholar
• Boppana SB, Fowler KB, Britt WJ, Stagno S, Pass RF. Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus. Pediatrics104(1 Pt 1), 55–60 (1999).
   PubMed Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med.202(5), 673–685 (2005).
   PubMed Web of Science ®Google Scholar
• Schleiss MR. Cytomegalovirus vaccine development. Curr. Top. Microbiol. Immunol.325, 361–382 (2008).
   PubMed Web of Science ®Google Scholar
• Slezak SL, Bettinotti M, Selleri S, Adams S, Marincola FM, Stroncek DF. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J. Transl. Med.5, 17 (2007).
   PubMedGoogle Scholar
• Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev. Mol. Med.10, e33 (2008).
   PubMedGoogle Scholar
• Bernstein DI, Reap EA, Katen K et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine28(2), 484–493 (2009).
   PubMed Web of Science ®Google Scholar
• Reap EA, Morris J, Dryga SA et al. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine25(42), 7441–7449 (2007).
   PubMedGoogle Scholar
• Selinsky C, Luke C, Wloch M et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccin.1(1), 16–23 (2006).
   Google Scholar
• Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet.55, 25–40 (2005).
   PubMed Web of Science ®Google Scholar
• Wloch MK, Smith LR, Boutsaboualoy S et al. Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects. J. Infect. Dis.197(12), 1634–1642 (2008).
   PubMed Web of Science ®Google Scholar
• Go V, Pollard RB. A cytomegalovirus vaccine for transplantation: are we closer? J. Infect. Dis.197(12), 1631–1633 (2008).
   PubMedGoogle Scholar
• Goonetilleke N, Moore S, Dally L et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime–boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J. Virol.80(10), 4717–4728 (2006).
   PubMed Web of Science ®Google Scholar
• Smith LR, Wloch M, Guterwill D, Rolland A, Chu A, Moss R. Preliminary Phase 2 immunogenicity results of a CMV DNA vaccine in hematopoietic cell transplant (HCT) recipients. Ann. Conf. Vaccine Res.25, S23 (2009).
   Google Scholar
• Schleiss MR. VCL-CB01, an injectable bivalent plasmid DNA vaccine for potential protection against CMV disease and infection. Curr. Opin. Mol. Ther.11(5), 572–578 (2009).
   PubMedGoogle Scholar
• Plotkin SA, Higgins R, Kurtz JB et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation58(11), 1176–1178 (1994).
   PubMed Web of Science ®Google Scholar
• Plotkin SA, Farquhar J, Horberger E. Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J. Infect. Dis.134(5), 470–475 (1976).
   PubMed Web of Science ®Google Scholar
• Adler SP, Starr SE, Plotkin SA et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J. Infect. Dis.171(1), 26–32 (1995).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J. Clin. Virol.35(3), 332–337 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Sinclair E, Bredt B et al. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. Vaccine24(25), 5311–5319 (2006).
   PubMed Web of Science ®Google Scholar
• Jacobson MA, Adler SP, Sinclair E et al. A CMV DNA vaccine primes for memory immune responses to live-attenuated CMV (Towne strain). Vaccine27(10), 1540–1548 (2009).
   PubMedGoogle Scholar
• Heineman TC, Schleiss M, Bernstein DI et al. A Phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J. Infect. Dis.193(10), 1350–1360 (2006).
   PubMed Web of Science ®Google Scholar
• Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev.13(1), 83–121 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson SR, Wilson JH, Buonocore L, Palin A, Rose JK, Reuter JD. Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity. Comp. Med.58(2), 129–139 (2008).
   PubMed Web of Science ®Google Scholar
• Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA89(22), 10847–10851 (1992).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Li Z et al. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine25(6), 1132–1141 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Maas R et al. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol.78(8), 3965–3976 (2004).
   PubMed Web of Science ®Google Scholar
• Frey SE, Harrison C, Pass RF et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J. Infect. Dis.180(5), 1700–1703 (1999).
   PubMed Web of Science ®Google Scholar
• Pass RF, Duliege AM, Boppana S et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J. Infect. Dis.180(4), 970–975 (1999).
   PubMed Web of Science ®Google Scholar
• Rasmussen L, Matkin C, Spaete R, Pachl C, Merigan TC. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis.164(5), 835–842 (1991).
   PubMedGoogle Scholar
• Frey SE, Newman FK, Yan L, Lottenbach KR, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA289(24), 3295–3299 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Lacey SF et al. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection. J. Clin. Virol.35(3), 324–331 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Z, La Rosa C, Mekhoubad S et al. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood104(3), 847–856 (2004).
   PubMed Web of Science ®Google Scholar
• La Rosa C, Wang Z, Lacey SF et al.In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp. Hematol.34(4), 497–507 (2006).
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhou W, Srivastava T et al. A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. Virology377(2), 379–390 (2008).
   PubMed Web of Science ®Google Scholar
• Yue Y, Wang Z, Abel K et al. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med. Microbiol. Immunol.197(2), 117–123 (2008).
   PubMedGoogle Scholar
• Zhong J, Khanna R. Ad-gBCMVpoly: a novel chimeric vaccine strategy for human cytomegalovirus-associated diseases. J. Clin. Virol.46(Suppl. 4), S68–S72 (2009).
   PubMed Web of Science ®Google Scholar
• Shanley JD, Wu CA. Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. Vaccine21(19–20), 2632–2642 (2003).
   PubMed Web of Science ®Google Scholar
• Shanley JD, Wu CA. Intranasal immunization with a replication-deficient adenovirus vector expressing glycoprotein H of murine cytomegalovirus induces mucosal and systemic immunity. Vaccine23(8), 996–1003 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao P, Ma D, Yan S et al. Towards a novel vaccine against human cytomegalovirus based on a chimeric Ad5F35 adenovirus vector expressing the immunodominant antigenic domain 1 epitope. Intervirology52(1), 35–42 (2009).
   PubMedGoogle Scholar
• Zhong J, Rist M, Cooper L, Smith C, Khanna R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS One3(9), e3256 (2008).
   PubMed Web of Science ®Google Scholar
• Britt WJ, Jarvis MA, Drummond DD, Mach M. Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B. J. Virol.79(7), 4066–4079 (2005).
   PubMedGoogle Scholar
• Elkington R, Walker S, Crough T et al.Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J. Virol.77(9), 5226–5240 (2003).
   PubMed Web of Science ®Google Scholar
• Elkington R, Shoukry NH, Walker S et al. Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H. Eur. J. Immunol.34(11), 3216–3226 (2004).
   PubMed Web of Science ®Google Scholar
• Manley TJ, Luy L, Jones T, Boeckh M, Mutimer H, Riddell SR. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood104(4), 1075–1082 (2004).
   PubMed Web of Science ®Google Scholar
• Lazzarotto T, Guerra B, Lanari M, Gabrielli L, Landini MP. New advances in the diagnosis of congenital cytomegalovirus infection. J. Clin. Virol.41(3), 192–197 (2008).
   PubMed Web of Science ®Google Scholar
• Cicin-Sain L, Bubic I, Schnee M et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol.81(24), 13825–13834 (2007).
   PubMedGoogle Scholar
• Mohr CA, Cicin-Sain L, Wagner M et al. Engineering of cytomegalovirus genomes for recombinant live herpesvirus vaccines. Int. J. Med. Microbiol.298(1–2), 115–125 (2008).
   PubMedGoogle Scholar
• Messerle M, Crnkovic I, Hammerschmidt W, Ziegler H, Koszinowski UH. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Natl Acad. Sci. USA94(26), 14759–14763 (1997).
   PubMed Web of Science ®Google Scholar
• Wagner M, Ruzsics Z, Koszinowski UH. Herpesvirus genetics has come of age. Trends Microbiol10(7), 318–324 (2002).
   PubMed Web of Science ®Google Scholar
• Dunn W, Chou C, Li H et al. Functional profiling of a human cytomegalovirus genome. Proc. Natl Acad. Sci. USA100(24), 14223–14228 (2003).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kobayashi M, McCauley RL, Herndon DN, Pollard RB, Suzuki F. Cadaveric skin allograft-associated cytomegalovirus transmission in a mouse model of thermal injury. Clin. Immunol.92(2), 181–187 (1999).
   PubMedGoogle Scholar
• Hahn G, Revello MG, Patrone M et al. Human cytomegalovirus UL131–128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol.78(18), 10023–10033 (2004).
   PubMed Web of Science ®Google Scholar
• Gerna G, Percivalle E, Lilleri D et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131–128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J. Gen. Virol.86(Pt 2), 275–284 (2005).
   PubMedGoogle Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl Acad. Sci. USA102(50), 18153–18158 (2005).
   PubMed Web of Science ®Google Scholar
• Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine26(45), 5760–5766 (2008).
   PubMed Web of Science ®Google Scholar
• Gerna G, Sarasini A, Patrone M et al. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J. Gen. Virol.89(Pt 4), 853–865 (2008).
   PubMed Web of Science ®Google Scholar
• Haller O, Weber F. Pathogenic viruses: smart manipulators of the interferon system. Curr. Top. Microbiol. Immunol.316, 315–334 (2007).
   PubMedGoogle Scholar
• DeFilippis VR. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv. Exp. Med. Biol.598, 309–324 (2007).
   PubMedGoogle Scholar
• Unterholzner L, Bowie AG. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem. Pharmacol.75(3), 589–602 (2008).
   PubMed Web of Science ®Google Scholar
• Brandt T, Heck MC, Vijaysri S, Jentarra GM, Cameron JM, Jacobs BL. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology333(2), 263–270 (2005).
   PubMedGoogle Scholar
• Hakki M, Marshall EE, De Niro KL, Geballe AP. Binding and nuclear relocalization of protein kinase R by human cytomegalovirus TRS1. J. Virol.80(23), 11817–11826 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall EE, Bierle CJ, Brune W, Geballe AP. Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J. Virol.83(9), 4112–4120 (2009).
   PubMed Web of Science ®Google Scholar
• Jentarra GM, Heck MC, Youn JW et al. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: scarification vaccination. Vaccine26(23), 2860–2872 (2008).
   PubMedGoogle Scholar